Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary class
AssigneeImmatics Biotechnologies GmbH
InventorsJens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
Life of this patent
Estimating the term…
Abstract
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Claims20
A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of IYLDRTLLTTI (SEQ ID NO:
- 56), wherein the cancer is non-small cell lung cancer adenocarcinoma (NSCLCadeno), squamous cell non-small cell lung cancer (NSCLCsquam), head and neck squamous cell carcinoma (HNSCC), gallbladder cancer (GBC), renal cell carcinoma (RCC), NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam (NSCLCother), esophageal cancer (OSCAR), gastric cancer (GC), uterine endometrial cancer (UEC), small cell lung cancer (SCLC), melanoma (MEL), hepatocellular carcinoma (HCC), and cholangiocellular carcinoma (CCC).
Dependencies are inferred from the claim text.